Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells

Ngozi Monu1, Alan B Frey

  • 1Department of Cell Biology, New York University Cancer Institute, New York University School of Medicine, New York, New York 10016, USA.

Cancer Research
|December 7, 2007
PubMed

Insights

Tumor-infiltrating lymphocytes (TIL) exhibit transient signaling defects upon tumor cell contact, caused by rapid p56(lck) inactivation mediated by Shp-1 phosphatase. This explains the loss of cytotoxic T cell function in tumors.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cell Signaling

Background:

  • CD8(+) tumor-infiltrating lymphocytes (TIL) often display impaired cytotoxic function within the tumor microenvironment.
  • This dysfunction is linked to proximal signaling deficits, including a failure in calcium flux and tyrosine kinase activation upon encountering tumor cells.

Purpose of the Study:

  • To investigate the transient nature of TIL signaling defects and identify the underlying molecular mechanisms.
  • To elucidate the role of specific signaling molecules, such as p56(lck) and Shp-1, in regulating TIL lytic function.

Main Methods:

  • Biochemical analysis of purified nonlytic and lytic TIL.
  • Assessment of p56(lck) activation kinetics and Shp-1 activity.
  • Investigating the colocalization of Shp-1 and p56(lck).
  • Inhibition of Shp-1 activity to assess its impact on TIL cytolysis.

Main Results:

  • TIL signaling defects are transient and reversible upon purification and brief culture.
  • Contact with tumor cells leads to rapid, transient activation and inactivation of p56(lck) in nonlytic TIL.
  • In contrast, lytic TIL show sustained p56(lck) activation.
  • Shp-1 phosphatase is highly active in nonlytic TIL, colocalizes with p56(lck), and its inhibition restores TIL cytolytic function.

Conclusions:

  • Tumor cell contact activates Shp-1 in nonlytic TIL, leading to rapid dephosphorylation and inactivation of p56(lck).
  • This Shp-1-mediated inhibition of p56(lck) is a key mechanism underlying the loss of effector functions in CD8(+) TIL.
  • The findings highlight a critical regulatory switch controlling cytotoxic T cell activity within the tumor microenvironment.

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...